Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEETING 65th JCA Annual Meeting to Be Held Sept. 28-30
September 18, 2006
- NEW PRODUCTS Novartis Pharma: Voltaren Tape L
September 18, 2006
- Bayer's Rivaroxaban Shows Efficacy in PII Trials
September 18, 2006
- Innovation Is Driven by Free Trade: Mr Taurel of Eli Lilly
September 18, 2006
- Toray, JT, and Torii to Codevelop the Antipruritic TRK-820
September 18, 2006
- SELF-MEDICATION NEWS IN BRIEF
September 18, 2006
- TMRC Expands Drug Development System
September 18, 2006
- Takara Bio Licenses Retronectin to MSKCC in the US
September 18, 2006
- Glutamic Acid Inhibits Bone Degradation: Prof. Moriyama
September 18, 2006
- Janssen to Upgrade MRs in Oncology, CNS
September 18, 2006
- FDA Reviewing Regulation on Emergency Research Without Informed Consent
September 18, 2006
- JRCS Considers Joint Purchase of Drugs
September 18, 2006
- R&D NEWS IN BRIEF
September 18, 2006
- BUSINESS NEWS IN BRIEF
September 18, 2006
- New System Automatically Prepares Tissue Sections: Kurabo
September 18, 2006
- Regional Core Hospitals to Be Networked to Stimulate Clinical Trials
September 11, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 11, 2006
- Takara Bio Discovers Potent Antitumor Activity of Kelp-derived Fucoidan
September 11, 2006
- Taisho Toyama Certifies 38 "Super MRs" in Field of Infectious Disease
September 11, 2006
- R&D NEWS IN BRIEF
September 11, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…